CD9 and prostate carcinoma: The aggressive DU145 and PC3 prostate cancer cells displayed reduced luciferase activity with the CD9 3’UTR compared to RWPE1 control (Figure 2D), which is indicative of endogenous regulatory factors acting within these cells to repress CD9 levels.